Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1968-1980
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1968
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1968
Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells
Chuan-Hong Li, Zhang-Ming Chen, Pei-Feng Chen, Lei Meng, Wan-Nian Sui, A-Man Xu, Wen-Xiu Han, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
Song-Cheng Ying, Department of Immunology, College of Basic Medicine, Anhui Medical University, Hefei 230022, Anhui Province, China
Author contributions: Li CH, Chen ZM, and Chen PF collected the data and wrote the manuscript; Sui WN participated in data analysis; Ying SC participated in discussion and language editing; Xu AM provided funding support; Han WX reviewed the manuscript and provided funding support; All authors contributed to the article and approved the submitted version.
Supported by the Natural Science Project of Anhui Province , No. KJ2021ZD0022 ; and the Key Research and Development Program of Anhui Province , No. 202104J07020029 .
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Affiliated Hospital of Anhui Medical University (Quick PJ 2019-09-01).
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Anhui Medical University (SC20200513).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest in this study.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email address hwxhbh@126.com . Participants gave informed consent for data sharing.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Xiu Han, MD, PhD, Professor, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Avenue, Shushan District, Hefei 230022, Anhui Province, China. hwxhbh@126.com
Received: May 30, 2022
Peer-review started: May 30, 2022
First decision: June 21, 2022
Revised: July 4, 2022
Accepted: August 21, 2022
Article in press: August 21, 2022
Published online: October 15, 2022
Processing time: 136 Days and 22 Hours
Peer-review started: May 30, 2022
First decision: June 21, 2022
Revised: July 4, 2022
Accepted: August 21, 2022
Article in press: August 21, 2022
Published online: October 15, 2022
Processing time: 136 Days and 22 Hours
Core Tip
Core Tip: Our study provides novel evidence that interleukin (IL)-34 contribute the growth and metastasis of gastric cancer (GC). IL-34 is up-regulated in GC cell lines and tissues, which is correlated with tumor size, grade of differentiation and tumor, node and metastasis stage. IL-34 enhances the ability of proliferation, clone formation, migration and invasion of GC cells and regulates the expression levels of epithelial-mesenchymal transition-associated proteins, suggesting that IL-34 may be an effective target for the therapy of GC.